IMvigor210 and IMvigor211 – analysis of individual participant data by Alberto Martini
Alberto Martini, Director of Research in the Division of Urology at University of Cincinnati, shared his recent article focused on analysis of individual participant data from IMvigor210 and IMvigor211, coauthored by Giuseppe Fallara, Dederico Belladelli et al..
“Concomitant antihistamine administration is associated with improved survival outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with atezolizumab. Analysis of individual participant data from IMvigor210 and IMvigor211”
“Histamine and histamine receptor H1 (HRH1) are frequently increased in the tumor microenvironment and induce T cell dysfunction.” – Dr Martini wrote on X, citing an article titled “The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1” by Hongzhong Li et al..
“In our study we aimed to assess the role of AntiH on oncological outcomes among patients treated with IO from 2 bladder cancer RCTs. We found that concomitant use of antihistamines was associated with prolonged PFS, CSS and OS.
Two sensitivity analyses confirmed our findings:
1. By excluding patients who developed immune-related AEs, as those patients might receive AntiH to treat irAEs’ symptoms.
2. By performing a landmark analysis fitted at the medianFU of the patients included in the study – patients have to make it till the administration of AntiH, introducing the possibility of immortal time bias (or a combo of immortal with lead time).” – Dr Martini shared on X, quoting his tweetorial from 2023:
“Check out our study on immune-related AEs (irAEs) to IO in patients with m+ or LA urothelial carcinoma. We relied on IPD of IM210/1 from Vivli. IO acts by de-inhibiting the immune system and reactions against self antigens are not uncommon.”
You might be interested in Immunotherapy for bladder cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023